The more compelling policy in the pharmaceutical industry is the centralized purchasing of medicines, centralized purchasing gives the people a cheaper price for higher quality medicines, through volume purchasing, volume for price, reduce the burden on patients, save the expenditure of the health insurance fund, enhance the efficiency of the use of the health insurance fund, and improve the level of medical protection for the people.
To the pharmaceutical enterprises due to the special nature of the collective purchasing, only suitable for competitive generic drugs, can prompt a certain strength of the generic drug companies to avoid the risk of transformation, the national organization of the collective purchasing of drugs will cover all regions of the country, the quality of the product, the supply of production capacity and cost control of the enterprise's requirements are higher, enterprises are facing greater competitive pressure, will be conducive to promoting the optimization and restructuring of the industry, and gradually change the industry scale Small, low-quality situation, and promote the industry scale, intensification and modernization.
Overall collectively there are advantages and disadvantages, collectively the disadvantage is that the profit will fall, but harvested more pharmaceutical market, the realization of the incremental increase, for the original product market share of small enterprises, as long as the drugs into the collectively, will not worry about the sale of drugs, saving the cost of promotions or marketing, for the long-term development of the enterprise is more good than bad.
In addition to collective purchasing, there is also a provincial model of bidding and purchasing of medicines, which also coexists. The two models constitute the mainstream domestic drug pricing and procurement model.
The fifth batch of drug collection data can be queried in the database, in the national centralized drug procurement database in the collection of batch selection, the fifth batch of collection data, you can query the fifth batch of drug collection of relevant data.
The fifth batch of data
The fifth batch of data has been fully announced, and now has begun the sixth batch of drug collection, the specific data has not been formally announced, but this year should be able to publish.